Prophase labs seeks to transform esophageal cancer detection and management with launch of its be-smart test in h2 2024

Garden city, ny, april 10, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase” or the “company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough be-smart test for esophageal cancer. the company is aiming for commercial launch in the second half of 2024.
PRPH Ratings Summary
PRPH Quant Ranking